BPI Labs, LLC et al. vs. Eli Lilly & Co.

Explore the PTAB proceeding IPR2025-01346 filed by BPI Labs, LLC et al. on 2025-08-04. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2025-01346

Filing Date

2025-08-04

Accorded Filing Date

2025-08-04

Institution Decision Date

2025-12-11

Last Modified Date

2026-03-18

Proceeding Type

IPR

Termination Date

2025-12-11

Trial Status

Discretionary Denial

Parties & Counsel

Petitioner

BPI Labs, LLC et al.

Represented By

Murphy, Jameset al

Patent Owner / Respondent

Eli Lilly & Co.

Represented By

Morin, Michaelet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 14987791

Respondent Patent Number 9474780

External Links

Espacenet

Google Patents

Respondent Inventor Bengt Krister Bokvist et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

48 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name ELI LILLY & COMPANY

Customer Number 25885

Address P.O. BOX 6288, PATENT DIVISION, INDIANAPOLIS, IN, 46206-6288, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
35241	James Leeds	317-276-1667
36711	Macharri Vorndran-Jones	317-276-1665
41264	Grant Reed	646-638-5003
43707	Gerald Keleher	317-276-3964
44646	Elizabeth Mcgraw	317-277-7443
45165	Robert Tucker	317-433-9829
45263	Arvie Anderson	317-277-7217
45609	Robert Sharp	317-651-1541
46903	Janet Martineau	206-715-7190
47145	Tina Tyson	317-277-3537
47504	Gregory Cox	317-277-2620
48613	Dan Wood	317-277-3366
48881	Gary Birch	317-276-0335
49013	Ann Chen	+86-21--2320-1399
50494	Bradley Crawford	2029628300
51417	Michael Asam	317-651-5646
51641	Ted Ebersole	317-433-2718
51820	Danica Hostettler	317-276-3711
52008	M Mcbride	414-277-5226
52373	Perry Woo	516-606-9772
56579	Nicole Woods	908-203-6835
57014	Yong Zhao	732-594-7338
57817	Congping Xie	317-433-2587
57909	Tonya Combs	317-651-1266
58241	Cedric D'Hue	176-541-25051
58392	Brian Cholewa	317-665-0387
59175	Bilyana Georgieva	317-800-8264
60723	Joseph Pletcher	317-277-4791
61806	Sanjay Jivraj	317-433-3495
61824	Marion Spillman	317-433-8735
62906	Jennifer Gregory	317-651-0116
63813	Robert Johnson	317-277-8747
64466	Jonathan Anderson	317-651-0640
65496	Matthew Lord	317-651-8072
66038	Thomas Weber	925-270-6764
66547	Duane Marks	317-521-2817
67097	Nicholas Kunz	602-790-8410
70773	Xiaoguang Gao	617-542-5070
71940	Parker Mccrary	317-719-7520
72408	Robert Shereda	734-489-8006
74850	Stefan Ochiana	202-970-3034
74973	Arthur Shum	617-526-6771
76145	Charles Rexer Jr.	212-301-0796
76639	Neelaabh Shankar	317-502-7117
77023	Shenshen Li	469-391-7451
78803	Gabriel Magallanes	317-276-2000
79494	Megan Fuller	317-586-1856
79584	Dipa Patel	908-704-2028

Proceeding Documents

171

Notice: refund approved NOTICE

2026-03-18 FILING PARTY: BOARD

Download

Request for Refund IPR2025-01346 OTHER

2026-03-13 FILING PARTY: PETITIONER

Download

Order Denying Director Review of Institution Decision REHEARING

2026-02-10 FILING PARTY: BOARD

Download

Authorized Response to Director Review Request OTHER

2026-01-16 FILING PARTY: PATENT OWNER

Download

Petitioner Request for Director Review REQUEST

2026-01-09 FILING PARTY: PETITIONER

Download

BPI Labs, LLC et al. vs. Eli Lilly & Co.

Proceeding Overview

Parties & Counsel

Petitioner

BPI Labs, LLC et al.

Represented By

Patent Owner / Respondent

Eli Lilly & Co.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Notice: refund approved NOTICE

Request for Refund IPR2025-01346 OTHER

Order Denying Director Review of Institution Decision REHEARING

Authorized Response to Director Review Request OTHER

Petitioner Request for Director Review REQUEST

Exhibit 3100 Exhibit

Director Discretionary Decision: Deny RESPONSE

EX1089 Quarterly Statements Exhibit

Ex. 2080 - Galien Foundation Website Exhibit

Ex. 2077 - Mounjaro FDA Approval Exhibit

Ex. 2061 - Timofte 2013 Exhibit

EX1090 ELI_LILLY_CO_10K_2025_V1 Exhibit

Ex. 2059 - Gattrell 2013 Exhibit

Ex. 2062 - Kueh 2014 Exhibit

Ex. 2057 - Knudsen 2001 Exhibit

Ex. 2095 - Eli Lilly & Co. Press Release, Lilly Reports 3rd Qtr 2025 Financial Results Exhibit

Ex. 2053 - Müller 2022 Exhibit

Ex. 2064 - USP Appl Publ 2016-0015788 A1 (Holscher) Exhibit

EX1087 Mounjaro Approval Exhibit

Ex. 2065 - Gao 2023 Exhibit

Ex. 2054 - USP11357820 (B2) Exhibit

Ex. 2084 - Sinha 2023 Exhibit

Ex. 2079 - PR Newswire (10.27.2023) Exhibit

Ex. 2067 - Teng 2010 Exhibit

Ex. 2081 - Eli Lilly & Co. 10-K (FY 2024) Exhibit

Ex. 2098 - DiMarchi Sequence Listings Exhibit

EX1091 Law360 - Data Undermines USPTOs Settled Expectations Doctrine Exhibit

EX1088 Zepbound Approval Exhibit

EX 1092 Acta Pharmaceutica Sina B Exhibit

Ex. 2074 - Zepbound Prescribing Information (Feb 2025) Exhibit

Disc Denial Opposition 11-12 (BFP)-FINAL RESPONSE

Patent Owner's Preliminary Response POPR

Ex. 2076 - Willard 2020 Exhibit

Ex. 2073 - Mounjaro Prescribing Information (May 2025) Exhibit

Ex. 2096 - Eli Lilly & Co., Q3 2025 Earnings Call Presentation Exhibit

EX1086 PTAB Leader Urges Specificity In Discretionary Denial Briefs - Law360 Exhibit

Ex. 2063 - Knudsen 2000 Exhibit

Ex. 2097 - STAT News (10.30.2025) Exhibit

Ex. 2078 - Zepbound FDA Approval Exhibit

Patent Owner's Updated Mandatory Notices NOTICE

Ex. 2015 - Pharmaceutical Technology (10.5.2018) Exhibit

Ex. 2090 - Eli Lilly Press Release (8.27.2024) Exhibit

Ex. 2027 - Rosenstock (Diabetes Care 2023) Exhibit

Ex. 2031 - Drug Discovery Development (6.3.2021) Exhibit

Ex. 2014 - Frias et al. (Lancet 2018) Exhibit

Ex. 2004 - Beauroyre (Abacum 6.25.2025) Exhibit

Ex. 2020 - Eli Lilly Press Release (6.21.2024) Exhibit

Ex. 2017 - Eli Lilly Press Release (12.9.2020) Exhibit

Ex. 2050 - Eli Lilly - Tirzepatide Non-NCT Clinical Trials (compilation) Exhibit

Ex. 2011 - Eli Lilly Q2 2016 Earnings Presentation Exhibit

Ex. 2044 - FDA, Orange Book-Approved Drug Products With Therapeutic Equivalence Evaluations, Tirzepatide Exhibit

Ex. 2006 - Fierce Healthcare (9.23.2011) Exhibit

Ex. 2028 - Hosie (Business Insider 6.6.2022) Exhibit

Ex. 2041 - Zacks Equity Rsch. (Nasdaq 12.10.2020) Exhibit

Ex. 2005 - CCRPS, Phase III Clinical Trials Definitive Guide & Case Studies (6.8.2025) Exhibit

Ex. 2029 - Chavda et al. (Molecules 2022) Exhibit

Ex. 2038 - Buntz (Drug Discovery Dev. 10.16.2023) Exhibit

Ex. 2092 - Eli Lilly Press Release (5.24.2024) Exhibit

Ex. 2013 - Eli Lilly Press Release (10.4.2018) Exhibit

Ex. 2034 - Biochem PEG (5.20.2022) Exhibit

Ex. 2089 - WO2010071807A1 DiMarchi Exhibit

Ex. 2003 - PhRMA Research Development Policy Framework (Sept. 2024) Exhibit

Ex. 2091 - Eli Lilly Press Release (2.26.2025) Exhibit

Ex. 2036 - Sainz (diaTribe Learn 9.21.2022) Exhibit

Ex. 2021 - Frias et al. (NEJM 2021) Exhibit